Hence, our data reveals the ZBTB16 DMP as a prominent epigenetic biomarker for GC treatment, and future studies should assess its utility in predicting clinical GC response in patients with inflammatory or autoimmune diseases receiving GC therapy. Here, ZBTB16 is linked to autoimmune disease.